← ANALYST RATINGS · TIPRANKS
Aclaris Therapeutics (ACRS): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy0 Hold0 Sell
Ratings of 5 analysts in the last 3 months12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $12.00, the highest $16.00, the lowest $10.00. The average is +265.9% from the last price of $3.28.
Analyst ratings 10
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.50 → $3.00−14.3% | Hold | −8.5% | Reiterated | 17.10.26on TipRanks 07:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.50 → $3.00−14.3% | Hold | −8.5% | Reiterated | 17.10.26on TipRanks 07:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.50 → $3.00−14.3% | Hold | −8.5% | Reiterated | 17.10.26on TipRanks 07:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.50 → $3.00−14.3% | Hold | −8.5% | Reiterated | 17.10.26on TipRanks 07:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.50 → $3.00−14.3% | Hold | −8.5% | Upgrade | 15.10.26on TipRanks 06:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.50 → $3.00−14.3% | Hold | −8.5% | Upgrade | 15.10.26on TipRanks 06:05 | — | |
| Biren Amin★★★★★★★★★★#1671 · hits 46% · avg +7.6% | Piper Sandler | $11.00 | Buy | +235.4% | Reiterated | 07.10.26on TipRanks 07:25 | −7.9%next day +11.9% · 5 days +0.4% | ↗ |
| Kate Dellorusso★★★★★★★★★★#5737 · hits 57% · avg +7.2% | LifeSci Capital | $13.00 | Buy | +296.3% | Reiterated | 01.10.26on TipRanks 17:15 | −1.2%next day −3.4% · 5 days −13.9% | ↗ |
| Edward Nash★★★★★★★★★★#204 · hits 52% · avg +29.5% | Canaccord Genuity | $10.00 | Buy | +204.9% | Initiated | 01.09.26on TipRanks 06:30 | +0.2%next day +2.2% · 5 days −7.7% | ↗ |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $16.00 | Buy | +387.8% | Reiterated | 10.08.26on TipRanks 06:27 | −0.1%next day +0.7% · 5 days +0.4% | ↗ |
| Adam Vogel★★★★★★★★★★#1113 · hits 79% · avg +38.0% | Craig-Hallum | $10.00 | Buy | +204.9% | Reiterated | 06.08.26on TipRanks 09:35 | −4.1%next day −3.6% · 5 days −5.0% | ↗ |
| Seamus Fernandez★★★★★★★★★★#129 · hits 66% · avg +30.6% | Guggenheim | $12.00 | Buy | +265.9% | Reiterated | 11.05.26on TipRanks 07:35 | +0.2%next day −1.3% · 5 days −11.0% | ↗ |
| Alex Thompson CFA★★★★★★★★★★#60 · hits 73% · avg +50.6% | Stifel Nicolaus | $4.00 | Hold | +22.0% | Reiterated | 08.05.26on TipRanks May 10 22:05 | +0.6%next day +0.2% · 5 days −8.5% | ↗ |
| Martin Fan★★★★★★★★★★#177 · hits 87% · avg +94.8% | Wedbush | $10.00 | Buy | +204.9% | Reiterated | 08.05.26on TipRanks 13:05 | +0.6%next day +0.2% · 5 days −8.5% | ↗ |
| Jeff Jones★★★★★★★★★★#749 · hits 46% · avg +20.3% | Oppenheimer | $10.00 | Buy | +204.9% | Reiterated | 08.05.26on TipRanks 08:45 | +0.6%next day +0.2% · 5 days −8.5% | ↗ |
| Unknown Analyst | Goldman Sachs | $10.00 | Buy | +204.9% | Reiterated | 16.04.26on TipRanks 12:35 | +1.0%next day +5.6% · 5 days +13.4% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Aclaris Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $12.00 at a price of $5.26 (+128.1%); now: $12.00 at $3.28 (+265.9%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 16 | 10 | 7 | 7 | 8 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.17 (from $-0.21 to $-0.15). Last quarter: $-0.15.
Sales
Next quarter’s sales estimate — $1M (from $0M to $2M). Last quarter: $2M.
Best top-analyst consensus in the sector · Healthcare
About Aclaris Therapeutics
- CEO: Neal S. Walker
- Employees: 71
- 640 Lee Road, Wayne, PA, 19087, US
- www.aclaristx.com
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
Data from the stock’s TipRanks forecast page, read 17 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗